DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 9-435/S-034

AstraZeneca LP
1800 Concord Pike
P.O. Box 8355
Wilmington, DE 19803-8355

Attention: Judy Firor
Director, Regulatory Affairs

Dear Ms. Firor:

Please refer to your supplemental new drug application dated August 27, 2003, received August 29, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Nesacaine and Nesacaine-MPF (chloroprocaine HCl) Injection.

Reference is also made to your submission dated May 13, 2004, which constituted a complete response to our February 24, 2004, action letter.

This supplemental new drug application provides for a revised package insert. A **Geriatric Use** subsection is added in accordance with the requirements of 21CFR 201.57(f)(10) to the **PRECAUTIONS** section.

We have completed our review of this application, as amended, and it is approved, effective on the date of this letter.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kimberly Compton, Regulatory Project Manager, at (301) 827-7410.

Sincerely,

{See appended electronic signature page}

Bob Rappaport, M.D.
Director
Division of Anesthetic, Critical Care, and
Addiction Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Bob Rappaport

6/21/04 05:55:26 PM